Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib with prophylactic Leucogen in RET fusion-positive advanced NSCLC (real-world, single-arm)
ChiCTR2600120202Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pralsetinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Grade and incidence of leukopenia and neutropenia at 1 month after first pralsetinib administration. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600120202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120202.